海峡药学
海峽藥學
해협약학
STRAIT PHARMACEUTICAL JOURNAL
2015年
4期
81-84
,共4页
林文盛%陈剑英%程文桃%罗兰珠%李凌恩%郭少楠%高明%郑典诚
林文盛%陳劍英%程文桃%囉蘭珠%李凌恩%郭少楠%高明%鄭典誠
림문성%진검영%정문도%라란주%리릉은%곽소남%고명%정전성
抑郁症%体质量%疗效%米氮平
抑鬱癥%體質量%療效%米氮平
억욱증%체질량%료효%미담평
Depression%Body weight%Treatment outcome%Antidepressant agents
目的:探讨抑郁症患者服用米氮平治疗后体重变化与其疗效的相关性。方法55例抑郁症患者接受米氮平单一抗抑郁药物治疗,开放性观察12周,以HDRS-17评价疗效,于基线及治疗后第一、二、四、八、十二周末重复测量体质量和HDRS-17评分,对连续性数据采用重复测量资料方差分析、Pearson相关分析和 ROC 分析。结果治疗12周后,患者平均体重增加值为(3.4±0.4) kg,HDRS-17总分明显改善( F =893.14,P=0.000),体重增加(F=2.43,P=0.035),差异均有统计学意义。治疗4周后,患者体重增加与量表减分率之间呈弱相关(r=0.270~0.306,P=0.044~0.022),但抑郁症状的早期改善对终点体重增加没有预测价值(AUC=0.64〔0.48-0.79〕)。结论米氮平所致患者体重增加与疗效呈弱相关相关,应注意相关健康教育以免影响患者的服药依从性。
目的:探討抑鬱癥患者服用米氮平治療後體重變化與其療效的相關性。方法55例抑鬱癥患者接受米氮平單一抗抑鬱藥物治療,開放性觀察12週,以HDRS-17評價療效,于基線及治療後第一、二、四、八、十二週末重複測量體質量和HDRS-17評分,對連續性數據採用重複測量資料方差分析、Pearson相關分析和 ROC 分析。結果治療12週後,患者平均體重增加值為(3.4±0.4) kg,HDRS-17總分明顯改善( F =893.14,P=0.000),體重增加(F=2.43,P=0.035),差異均有統計學意義。治療4週後,患者體重增加與量錶減分率之間呈弱相關(r=0.270~0.306,P=0.044~0.022),但抑鬱癥狀的早期改善對終點體重增加沒有預測價值(AUC=0.64〔0.48-0.79〕)。結論米氮平所緻患者體重增加與療效呈弱相關相關,應註意相關健康教育以免影響患者的服藥依從性。
목적:탐토억욱증환자복용미담평치료후체중변화여기료효적상관성。방법55례억욱증환자접수미담평단일항억욱약물치료,개방성관찰12주,이HDRS-17평개료효,우기선급치료후제일、이、사、팔、십이주말중복측량체질량화HDRS-17평분,대련속성수거채용중복측량자료방차분석、Pearson상관분석화 ROC 분석。결과치료12주후,환자평균체중증가치위(3.4±0.4) kg,HDRS-17총분명현개선( F =893.14,P=0.000),체중증가(F=2.43,P=0.035),차이균유통계학의의。치료4주후,환자체중증가여량표감분솔지간정약상관(r=0.270~0.306,P=0.044~0.022),단억욱증상적조기개선대종점체중증가몰유예측개치(AUC=0.64〔0.48-0.79〕)。결론미담평소치환자체중증가여료효정약상관상관,응주의상관건강교육이면영향환자적복약의종성。
ABSTRACT:OBJECTIVE To evaluate the correlation between body weight change and mirtazapine treatment outcome in patients with depression.METHODS The 12-week,open-label clinic trial included 55 eligible patients with depression.All received mirtazapine monotherapy, and efficacy was assessed by 17-item Hamilton Depression Rating Scale (HDRS-17).HDRS-17 score and body weight were measured at baseline and week 1,2,4,8,12 lat-er.Weight changes and treatment outcomes were respectively analyzed by repeated-measures ANOVA, correlations between them were computed by Pearson Correlations procedure, and ROC analysis was performed to estimate the predictive value of early improvement on depressive symptom at week 2 prognosticating final weight gain at week 12.RESULTS After 12-week treatment,there was a significant elevation of body weight ( F=893.14,P=0.000) , with an average increase of (3.4 ±0.4) kg.Meanwhile,there was also a significant improvement on HDRS-17 total scores (F=2.43,P =0.035).A markedly correlations between them existed,with a weak value of r =0.270 ~0.306 (P=0.044~0.022).However,early improvement on depressive symptom failed to predict final weight gain at week 12 ( AUC=0.55〔0.49~0.62〕) .CONCLUSIONS A moderate negative correlation between weight in-crease and treatment outcome is found in depressed patients treated with mirtazapine,indicating the importance of healthy education on body weight control to enhance medication compliance.